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Abstract 
Background  
The European Organisation for Research and Treatment of Cancer (EORTC) Group has 
developed a new multidimensional instrument measuring cancer related fatigue to be used in 
conjunction with the quality of life core questionnaire (EORTC QLQ-C30). The paper reports on 
the results of an international psychometric validation of the EORTC QLQ fatigue module, which 
is a multidimensional tool for assessing physical, cognitive and emotional aspects of cancer 
related fatigue. 
 
Methods 
The methodology follows the EORTC guidelines for phase IV validation of modules. We used a 
complex design assessing data in four cohorts of patients with a prospective longitudinal data 
collection. For validation and cross-validation confirmatory factor analysis (maximum likelihood 
estimation) was employed. Furthermore, sensitivity to change and test-re-test reliability have 
been examined. The study involved an international multi-centre collaboration of eleven 
European and Non-European countries.   
 
Results 
A total sample of 946 patients with various tumour diagnoses and in various stages of their 
disease were enrolled. Based on the confirmatory factor analysis, we assigned one item from 
one to another sub-dimension and removed one item to improve the scale structure, resulting in 
the EORTC QLQ-FA12. In addition, acceptable sensitivity to change as well very good test-
retest reliability has been proven. 
 
 3 
Conclusion 
The EORTC QLQ-FA12 is now available as a validated phase IV module with excellent 
psychometric characteristics, and can be used as a robust instrument for measuring cancer 
related fatigue in international clinical trials, in daily clinical routine or in quality assurance.  
 
Keywords 
Cancer related fatigue; cancer, international field validation, quality of life; module development; 
confirmatory factor analysis 
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Background  
Fatigue is one of the most distressing symptoms for cancer patients affecting their quality of life 
in all phases of the treatment or stages of the disease. Cancer related fatigue (CrF) is commonly 
defined as a self-recognised phenomenon that is subjective in nature and experienced as a 
feeling of tiredness or lack of energy that varies in degree, frequency and duration [1]. From a 
patient’s perspective, fatigue is described as an unusual feeling of exhaustion, weakness or a 
loss of activity with sequels to emotional and cognitive functions [2, 3], which, in general, can not 
be reduced by sleep or rest. Fatigue is the most frequent symptom occurring in cancer patients 
during or after medical treatment and also as a long term late effect. Prevalence rates ranging 
from 59%-100%, whereas fatigue as a long term sequelae or late effect is estimated to have an 
average prevalence rate of approximately 30%, dependent on the type of assessment and 
diagnostic criteria used [4,5,6]. Due to an increased interest and research output in CrF, more 
detailed uni- or multidimensional instruments have been developed to assess CrF (7,8]. While 
many of the fatigue scales have strengths and limitations, actually there are no clear 
recommendations which measure is the most appropriate. Using a standardized questionnaire 
allows clinicians to measure CrF in the course over time and allows comparisons between 
various patient subgroups. The EORTC QLQ-FA13 module has been developed following the 
methodological guidelines of EORTC, which include four phases of development (I. generation 
of issues, II. construction of items list III. pre-testing IV. field testing) [9]. The strengths of the 
questionnaires developed by EORTC Quality of life Group lie in an international multi-center 
approach following  high methodological standards and multicultural applicability. The pre-tested 
module EORTC QLQ-FA13 (phase III) is based on a multidimensional concept of fatigue 
including 13 items (2 global items on interference with daily activities and social sequelae of 
fatigue and 11 items allocated to a physical, emotional and cognitive domain) (see appendix A). 
It has been designed to measure fatigue in conjunction with the quality of life core questionnaire 
EORTC QLQ-C30 [10].  
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Aims and purpose 
According to the EORTC Quality of Life Group guidelines [9], the purpose of phase IV of the 
module development is the evaluation of the psychometric characteristics and the validity of the 
EORTC QLQ-FA13 in an international sample of tumour patients. The psychometric validation 
includes the evaluation of the scale structure of the EORTC QLQ-FA13 using confirmatory 
analyses. The main hypotheses for the factorial structure to be tested were the following:  
1. The factorial structure of the EORTC QLQ-FA13 phase III module may be replicated 
according to the underlying theory.  
2. The global items (endogenic variables) FA12 (“did fatigue interfere with your daily activities”) 
and FA13 (“did you have the feeling that fatigue was not understood by people close to you”) are 
predicted adequately by the sub-scales physical, cognitive and emotional fatigue. 
In addition we analysed test-retest reliability, internal consistency and the responsiveness to 
change. 
Design and Methods 
The design for the psychometric evaluation of the EORTC QLQ-FA13 followed the guidelines of 
EORTC for the development of modules in phase IV. Patients were enrolled in four distinct  
groups as following (see table 1):  
 group A: Cancer patients with first-line treatment with curative intention (t1A-t3A) 
 group B: Cancer patients with second-line treatment with palliative intention (t1B-t3B) 
 group C: Cancer patients off treatment (≥12 and ≤ 18 months since end of treatment and 
no evidence of cancer disease or recurrence) (t1C,t2C) 
 group D: Cancer patients off treatment (≥ 36 and ≤ 72 months (survivors) and no 
evidence of cancer disease or recurrence (t1D,t2D) 
 
Insert table 1 here  
 
 6 
The patient’s questionnaire includes the EORTC core questionnaire (EORTC QLQ-C30 version 
3.0) and the fatigue module EORTCQLQ-FA13 in all four groups. In addition, for patients of the 
groups A and B, a global screening of Cancer Related Fatigue (CRF) was used to determine an 
initial global fatigue score according to the NCCN guidelines 2015. All patients provided clinical 
and socio-demographic data (gender, date of birth, country of origin, marital status, education 
level, employment status). Time since diagnosis, tumour locations, type of treatments, 
metastases, ECOG Performance Status, and time since completion of treatment (only for groups 
C and D) were taken from the medical records at each cooperating center.  
 
The study was carried out as an international multicentre study including 17 centres in 11 
European and Non-European countries (Europe: England, France, Germany, Austria, Poland, 
Netherlands, Sweden, Spain, Italy, Non-Europe: Egypt and Taiwan). For phase IV the EORTC 
QLQ-FA13 has been translated to the languages of the cooperating countries. The translations 
were carried out in close cooperation with the translation team of the Quality of Life Department 
of EORTC following the translation guidelines of EORTC QoL group [11]. We initially calculated 
a sample of 135 per group (over all group a total of n=520 patients [12]. Due to higher drop out 
rates than expected, we increased recruitment and sample size up to the final sample of n=946 
patients. Patient recruitment was from February 2011 to November 2014. The study was 
registered with the German Clinical Trial Studies Registry (DRKS-ID: DRKS00003091). 
National and local ethics approvals were obtained for the recruiting centers before 
commencement of this study. 
 
Inclusion and exclusion criteria 
 
Patients with cancer of all tumour sites were included if they met the following criteria: 
Histologically confirmed cancer, with written informed consent and the ability to understand the 
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language of the questionnaire. Patients had to have an absence of severe psychiatric or 
cognitive mental conditions potentially hampering compliance with the study protocol and follow-
up schedule, and all patients had to be aged over 18 years. Patients undergoing allogeneic 
hematological stem cell transplantation (HSCT) or neoadjuvant therapy were excluded. Patient 
could not participate in other quality of life studies that might interfere with this validation study.  
 
Statistical methods 
Data entry, management and statistical evaluation were conducted from the coordination centre 
in Freiburg. Data analysis was done using SPSS v21 supported from a biostatistician specialized 
in psychometric analyses. For the confirmatory factor analysis, AMOS 21.0 (Analysis of Moment 
Structures, maximum likelihood method) was used. Missing values (<13) were replaced with 
stochastic-regression-based imputation available in AMOS 21.0 [13]. This estimation procedure 
uses information within the available data information, to avoid biases in the analysed variance-
covariance matrix. Hence, the analysed information is not affected, if data are missing because 
of missing-at-random processes [14]. The assumption of normal distribution was checked by 
Mardia test in AMOS 21.0 and corrected in case of violation using the Bollen-Stine-Bootstrap 
strategy [15]. Item characteristics are described in terms of acceptance (percentage of 
responders), item discrimination (corrected item scale correlation) and item difficulty (mean 
score). Reliability was determined by score for internal consistence (Cronbach’s alpha) [15]. The 
a priori defined factor structure was checked by the discrepancy between the empirical based 
variance-covariance matrix and the variance-covariance matrix based on the model. For the 
evaluation of the model, indices of global and local fitness were used. Chi-square test was used 
for the statistical testing of the model. Further indices for the goodness of fit were Root-Mean-
Square-Error of Approximation (RMSEA) and Goodness of Fit Index (GFI) as absolute fit-
Indices. Normed Fit Index (NFI), Tucker-Lewis Index (TLI) und Comparative Fit Index (CFI) were 
used as measures for incremental fit and the Adjusted Goodness of Fit Index (AGFI). RMSEA 
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scores <.08 indicates an acceptable fit, score <.05 a good model fit. GFI scores >.95 are 
indicating a good model fit, scores >.90 an acceptable model fit [13]. For the estimation of the 
reliability of the single items, local fit indices were calculated. For convergent validity, the 
indicator reliability should be > .4 factor reliability > .6 and DEV (mean variance) > .5 [16]. For 
sensitivity to change we used MANOVA with standardized effect sizes (ηp² = partial eta-
squared) analysing the data of group A and B separately as differences between the two groups 
are to be expected. For univariate comparisons we used t-tests and for interpretation of the 
effect sizes we followed Cohen (1988) (d<0.1 = small effect; d<0.3 = medium effect; d> 0.5 = 
large effect). For test-re-test reliability we used intra-class correlation with the data of group C 
and D. 
 
Results 
Description of the sample  
The total sample of patients recruited in all groups was n=946. The average age was 58.7 (sd 
13.1 years) (range from 22-97 years). Patients were recruited in Germany (16.1%) and Poland 
(15.6%) followed by UK (11.1%), Sweden (10.0%), Egypt (9.9%), Spain (8.4%), Netherlands 
(7.2%), Italy (5.0%), Austria (4.5%) and Taiwan (3.8%). Gender distribution was balanced 
(female 54.1 %, male 45.9%). The sample comprised of a wide spectrum of tumour diagnoses 
with the highest percentages in breast cancer (24.0%) head and neck cancer (22.6%), lung 
cancer (11.1%) and colorectal cancer (9.5%) (for further details see table 2).  
Insert table 2 here  
Confirmatory factor analysis 
We use confirmatory analysis (CFA) to check the three factorial model of the EORTC 
QLQ-FA13 including the t1ABCD measurement of patients of all four groups (A to D) (n=944) (see 
figure 1). We used the two global items as indicators of the three latent constructs, as these two 
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items are not underlying the latent construct but represent potential effects of fatigue on daily 
and social life (see appendix A).  
The results of the CFA show that the underlying model of the EORTC QLQ-FA13 was not 
adequately reproduced by the data both for global (table 3) and local fit indices (table 4).  
 Insert tables 3 and 4 here 
The indices in table 3 show that the thresholds for acceptable model fit were not reached. The 
residual covariance suggest that item FA05 (“Did you have trouble getting things started?“) is 
indicative for the physical domain (increase of factor loading from 70 to .79) (table 3). Item FA05 
is more closely associated to the dimension of physical fatigue which includes items of reduced 
physical functions and loss of performance. Therefore, the allocation of item FA05 from the 
cognitive to the physical dimension is acceptable. Furthermore, Item FA11 (“Did you have 
trouble completing things?”) was insufficiently associated with the cognitive fatigue construct. 
Additionally, elimination of item FA11 caused considerable lower correlation between the latent 
construct in the model: the correlation between the cognitive and emotional fatigue decreased 
from r = .74 to .58, as well as between cognitive and physical fatigue from r = .73 to .66. Hence, 
after deleting the hybrid item FA11 from the scale the discriminability of the three constructs is 
noticeably enhanced and all fit indices and factor loading (all ≥ .72) could be substantially 
improved, respectively. Especially, the Bayesian Information criterion (BIC: 424.521), taking 
model parsimony into account, indicates the three-factorial model structure as the most 
appropriate.   
 Figure 1 for the previous model and figure 2 for the revised model show a graphical illustration 
of these results.   
 Insert figure 1 and 2 here  
To check the stability and generalisation of the structure equation model, a cross-validation of 
the results of the patients of all four groups at the time measurement t2ABCD was conducted. The 
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sample for cross validation included n= 643 patients. The results of the cross validation analysis 
show nearly identical model fit (AGFI= 0.921; RMSEA= 0.070; CFI= 0.970; indicator reliabilities 
from .52 to .81). Furthermore, the model estimations for the data of t2ABCD or t3AB confirmed the 
revised model for EORTC FA12 (see table 3). Given these results, the structure equation model 
could be conclusively replicated both in the cross-validation sample and based on the t2 resp. t3 
data. 
In terms of construct validity, patients with distant metastases had a significant higher score of 
overall fatigue than patients without distant metastases (M (metastases) = 2.09; M (no 
metastases = 1.69; t (262.4) = 6.93; p<.001; d= 0.63). Patients undergoing radiotherapy alone 
have a significant lower overall fatigue compared with patients with others therapies (M 
(radiotherapy) = 1.71; M (others) = 1.83; t (714) = -2.39; p = 0.017; d = 0.20). There was no 
significant difference between patients undergoing combined adjuvant therapy vs. monotherapy 
(t (714) = -1.53; p = 0.127). As we hypothesised, we found a significant correlation of the fatigue 
scores with the ECOG Score for all subscales (physical Fatigue: rs = .481; p<.001; Emotional 
Fatigue: rs = .322; p<.001; Cognitive Fatigue: rs = .328; p<.001). Post-hoc comparison of scores 
(Tukey Test) showed that patients of the group B (palliative treatment) have the highest fatigue 
scores compared with all other groups (MB = 2.10; MA = 1.75; MC = 1.69; MD = 1.67). In 
addition, there is a high negative correlation between fatigue in all subscales and the global 
quality of life (r = -.672; p<.001) showing the higher the fatigue the lower the global quality of life.   
 
Sensitivity to change  
 
For the analysis of sensitivity to change, we used data from all points of measurements (t1, t2, 
t3) of the subgroups A (curative treatment) and B (palliative treatment). Time between t1 and t2 
was on an average of 6.1 weeks for group A and 5.6 weeks for group B. Time difference 
between t1 and t3 was on an average of 20.1 weeks for group A and 13.8 weeks for group B.  
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In group A (curative treatment), fatigue scores for all subdimensions increased up to t2 and 
slightly decreased at t3. We found for all subdimensions significant changes (p<.05) with a small 
to medium effect size for physical fatigue (ηp² = 0.19) (Eta squared coefficient) and small effect 
sizes for the emotional (ηp² = 0.11) and cognitive fatigue (ηp² = 0.09) (table 5). Furthermore, 
there was a highly significant multivariate effect of time (p <.001) and highly significant 
interaction effect (p<.001). For group B (palliative treatment) we found no significant changes for 
the subdimensions physical fatigue and emotional fatigue with only very small effects sizes of 
ηp² = 0.03 resp. 0.06) (table 6). Only for the subscale cognitive fatigue we found a significant 
change comparing t2 and t3 (p<.05) with only a small effect size (ηp² = 0.06). Similarly, no 
multivariate effects (time or interaction of dimension and time) could be detected. The overall 
fatigue scores in all subdimensions were higher in the palliative group than in the curative group.  
 
    Insert table 5 and 6 here   
 
Test-Retest-Reliability 
 
Test-retest reliability was tested using the data of patients of group C and D (n=410). The time 
difference between t1CD and t2CD was an average of 9.3 days (SD= 7.41). As the results of both 
subgroups were very similar, we report the results for both groups together (see table 7). The 
correlations (Intra Class Correlation) for t1CD and t2CD in both groups show high scores for all 
three subdimensions ranging from r = .90 to .92 indicating a high stability of measurement. In 
addition, internal consistency was good with Cronbach’s alpha ranging from 0.79 to 0.88 for t1CD 
and 0.82 to 0.89  for t2CD (table 7).  
 
    Insert table 7 here  
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Discussion 
We conducted a comprehensive psychometric validation of the EORTC fatigue module FA13. As 
a result of our study, we present a slightly revised phase IV module, the EORTC QLQ-FA12. 
The international cross-cultural validation of this module, including a large and representative 
sample of cancer patients, allows generalization of the results and guarantees the cross-cultural 
applicability of this module, in line with the EORTC tradition. We used a confirmatory factor 
analysis to validate the a-priori three dimensional structure of EORTC QLQ-FA13 in conjunction 
with the two global items as criteria. The results show that the previous phase III module EORTC 
QLQ-FA13 did not reach a sufficient model fit for all items and therefore had to be modified. The 
changes include the elimination of a single item (FA11) and the allocation of one item (FA05) to 
the physical dimension instead of the cognitive dimension. The inter-correlation of FA11 within 
the factorial structure show that this item may be not sufficiently understood as part of the 
cognitive dimension. In addition, item FA11 did not allow a clear allocation to the three 
dimensions and shows low factor loading in all three factors ≤.35. As there is only a minor loss of 
information we decided to eliminate this item. The allocation of item FA05 to the physical 
dimension improved the model fit substantially. In total, by these changes the model could be 
improved and we attained very good scores for the model fit. A cross-validation of the data and 
the replication of the model for the t2 and t3 measurements confirmed the results of the revised 
model. In terms of convergent and divergent validity, all coefficients for the model fit showed 
very good to excellent fit. 
The two global items (FA12 and FA13) were used as criteria variables. Item FA12 was predicted 
by the physical dimension, FA13 by the cognitive dimension. These results are in line with the 
model assumptions, although we expected the prediction of these two items by all three 
dimensions. As a result, acceptable to very good scores for the internal reliability (Cronbachs α 
from .79 to .90) were found.  
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High correlations between the subscales of EORTC FA13 with sociodemographic or medical 
parameters confirmed the convergent validity and are line with the research literature [2,3,6,17].  
Analysis of test-retest reliability was conducted in two groups of patients both off treatment. The 
results show a high correlation for all fatigue scores between t1CD and t2CD with an average time 
difference of nine days which indicates a stable measurement of fatigue by the EORTC QLQ-
FA12 over a time where no changes of fatigue are to expect. 
The analyses of the sensitivity to change detected different results for the patients in curative 
treatment (group A) compared with patients under palliative treatment (group B).  In group A, we 
found small effects in all subdimensions of EORTC QLQ-FA12 for the pairwise comparisons of 
all three points of measurement (before treatment up to the end of treatment). In this group we 
covered a time distance from t1 to t3 of more than 5 months. In group B there was only a very 
small effect in the subdimension of cognitive fatigue. In all other dimensions we found no 
significant change over time. From a clinical point of view, all these results make sense, 
especially in patients in palliative care, who are suffering mostly from long lasting fatigue which 
may be not changed during ongoing treatment [18]. In addition, the time distance of the palliative 
care group was with 3.5 months shorter than in group A.  
Our study had some limitations. First, we could not achieve equal sample sizes for all 
cooperating countries, as the patient recruitment proceeded at different levels of recruitment in 
the various countries. Also, the recruitment in the palliative care group (group B) was more 
difficult to both recruit and when included we had drop out rates higher than initially planned. We 
were able to compensate losses in statistical power this, to some extent, by increasing the initial 
patient numbers and therefore we do not think this had any major impact on the findings of our 
analysis. As drop out is associated with disease related aspects, potential biases resulting from 
not-completely at random (MCAR) or randomly (MAR) missing data processes [15] may affect 
estimates or sensitivity for change and retest-reliability. 
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In conclusion, the EORTC QLQ-FA12 is now available as an internationally validated phase IV 
module to be used for measuring cancer related fatigue in conjunction with the EORTC QLQ-
C30, but there is still a need for further analysis of the sensitivity to change especially in 
palliative care patients. EORTC QLQ-FA12 may be also used to assess fatigue symptoms in 
clinical routine or quality assurance to assess care needs. The module is currently available in 
the following languages: English, Dutch, German, Polish, Italian, French, Spanish, Swedish, 
Norwegian, Arabic and Mandarin and is available from the EORTC Quality of Life Department.  
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Table 1 Overview: Design and analyses of the four groups 
 Group A Group B Group C Group D 
Points of measurement     
t1 T1A 
±7 days before or 
at the 1st day of 
treatment 
(adjuvant chemo-
/radiotherapy) 
(n = 311) 
T1B 
±7 days before or 
at the 1st day of 
treatment 
(adjuvant chemo-
/radiotherapy) 
(n = 222) 
T1C 
after completion of 
any treatment for 
at least 12 
respectively 
(n= 212) 
T1C 
after completion of 
any treatment for 
at least 36 months 
 
(n=199) 
t2 T2A 
ChTh: at the end of 
2nd cycle or at the 
beginning of the 
3rd cycle;  
Radioth.: at the 
end of the 4th 
week of 
radiotherapy 
(n= 279)  
(drop out: 10.3%) 
T2B 
ChTh: at the end of 
2nd cycle or at the 
beginning of the 
3rd cycle;  
Radioth.: at the 
end of the 4th 
week of 
radiotherapy 
(n = 181)  
(drop out: 18.5%) 
T2C 
re-test one week 
after first 
assessment 
(n=201) 
(drop-out: 5.1%) 
T2C 
re-test one week 
after first 
assessment 
(n = 187) 
(drop-out:  6%) 
t3 T3A 
at three months 
(range: 12-15 
weeks) after 
treatment 
(n=243)  
(drop-out: 12.9%) 
T3B 
at one month 
(range: 4-6 weeks) 
after treatment. 
 
(n =141) 
(drop-out: 22.1%) 
- - 
Analyses     
 Confirmatory 
Analyses  
Confirmatory 
Analyses 
Confirmatory 
Analyses 
Confirmatory 
Analyses 
 Sensitivity to 
change 
Sensitivity to 
change 
Test Re-Test 
Reliability  
Test- Re-Test 
Reliability  
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Table 2 Sociodemographic and medical data  
 
1 Due to the definition of groups C and D patients with metastases were excluded from the test-re-test analyses 
 
 
 
 
 
 
 
 
 
 
 
Total n=946 
(at t1 ABCD) 
Total 
Sample 
 
n = 946 
(100%) 
Group A 
Curative 
treatment 
n=311 
(32.9%) 
Group B 
Palliative 
Treatment 
n=222  
(23.5%) 
Group C 
off treatment 
<12 months 
n=212  
(22.4%) 
Group D 
off treatment 
>36 months 
n=199 
(21.1%) 
Age Mean (SD) (N=943) 58.8 (13.1) 59.3 (14.0) 62.7 (11.6) 58.7 (12.9) 59.0 (13.5) 
Range  22-97 26-87 31-97 28-90 25-95 
Sex      
Female 512 (54.1%) 157 (50.5 %) 118 (53.2) 125 (59%)  110 (55.3%) 
Male 434 (45.9%)  154 (49.5%) 104 (46.8%) 87 (41.0%) 89 44.7%) 
ECOG Score (N= 861;  91.0 %)      
0 Fully active 399 (46.3%) 151 (48.6%) 40 (18.0%) 99 (46.7%) 108 (54.3%) 
I  Restricted 303 (35.2%) 103 (33.1%) 94 (42.3%) 54 25.5%) 52 (26.1%) 
II Self care 121 (14.0%) 35 (11.3%) 58 (26.1%) 15 (6.6%) 14 (7.0%) 
III Limited self care 29 (3.4%) 8    (2.6%) 18 (8.1%) 1(0.5%) 2 (1.0%) 
IV Completely disabled 9 (1.1%)  1 80.3%) 5 (2.3%) 1 (0.5%) 2 (1.0%) 
Metastases  
(N= 903; 95.6 %) 
       
No 671 (74.3%) 275 (88.4%) 35 (15.8%) 190 (89.6%) 169 (84.9 %) 
Yes 231 (25.7 %) 31 (10.0%) 178 (80.2%) 11 (5.2%)1 12 (6.0%)1 
Location of tumour      
Breast 227 (24.0%) 60 (19.3%) 41 (18.5%) 75 (35.4%) 49 (24.6%) 
Head/Neck 214 (22.6%) 90 (28.9%) 32 (14.4%) 48 (22.6%) 44 (22.1%) 
Lung 105 (11.1%) 42 (13.5%) 50 (22.5%) 8 (3.8%) 5 (2.5%) 
Colorectal 90 (9.5%) 33 (10.6%) 23 10.4%) 17 (8.0%) 17 (8.5%) 
Prostate 61 (6.4%) 16 (5.1%) 5 (2.3%) 14 (6.6%) 26 (13.1%) 
Gynaecological 61 (6.4%) 18 (5.8%) 16 (7.2%) 13 (6.1%) 14 (7.0%) 
Haematological 49 (5.2%) 20 (6.4%) 7 (3.2%) 12 (5.7%) 10 (5.0%) 
Testicular 14 (1.5%) 3 (1.0%) 1 (0.5%) 4 (1.9%) 6 (3.0%) 
Pancreatic 13 (1.4%) 1 (0.3%) 12 (5.4%) 0 (0.0%) 0 (0.0%) 
Others    118 (12.5%) 30 (9.6%) 48 (21.8%) 15 (7.1%) 25 (12.6%) 
Treatment (multiple choice)      
Surgery 599 (63.3%) 159 (51.1%) 112 (72.5%) 176 (83.0%) 150 (75.4%) 
Chemotherapy 528 (55.8%) 178 (57.2%) 161 (50.5%) 103 (48.6%) 85 (42.7%) 
Radiotherapy 528 (55.8%) 141 (45.3%) 136 (61.3%) 129 (60.8%) 120 (60.3%) 
Hormone 83 (8.8%) 8 (2.6%) 17 (7.7%) 32 (15.1%) 25 (12.6%) 
Others 59 (6.2%) 11 (3.5%) 22 (9.9%) 11 (5.2%) 15 (7.5%) 
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Table 3: Gobal indices of convergent and divergent validity of the revised model (n=944)  
(data of t1ABCD) 
 c² p df c²/df GFI AGFI NFI RMSEA CFI TLI 
Thresholds 
for 
acceptable fit 
   
>0.05 
   
<3 
 
≥ 0.90 
 
≥ 0.90 
 
≥ 0.90 
 
≤ 0.08 
 
≥ 0.90 
 
≥ 0.90 
Thresholds 
for 
good fit 
   
>0.05 
   
<3 
 
≥ 0.95 
 
≥ 0.95 
 
≥ 0.95 
 
≤ 0.05 
 
≥ 0.95 
 
≥ 0.95 
 
EORTC QLQ-FA12 
 
Original 
model t1 
(EORTC-FA13) 
 
788.8 
 
<0.001 
 
58 
 
13.60 
 
0.888 
 
0.824 
 
0.894 
 
0.116 
 
0.901 
 
0.866 
 
Modified 
model t1 
(EORTC-FA12) 
 
205.1 
 
<0.001 
 
47 
 
4.36 
 
0.965 
 
0.942 
 
0.970 
 
0.060 
 
0.976 
 
0.967 
 
Modified 
model t2 
 
257.5 <.001 47 5.48 .957 .929 .966 .069 .972 .961 
 
Modified 
model t3 
 
342.4 <.001 47 7.28 .946 .911 .960 .82 .965 .951 
GFI= Goodness of fit index, AGFI= adjusted goodness of fit index, NFI= normed fit index, RMSEA= root mean square error of 
approximation, CFI= comparative fit index, TLI= Tucker-Lewis index 
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Table 4 Local indices of convergent and divergent validity of the revised model (n=944) (data of 
t1ABCD) 
Factor Item Indicator-
reliability 
t-Value  
of factor 
loading  
Factor-
reliability 
Average 
variance 
extracted 
Cronbach’s 
α 
Thresholds for 
acceptable fit1 
   
≥ 0.4 
 
  
 
≥ 0.6 
 
≥ 0.5 
 
>.70 
 
Physical  
 
 
FA01 
FA02 
FA03 
FA04 
FA052 
 
.85 
.87 
.81 
.73 
.77 
 
34.00 ***  
30.57 *** 
25.77 *** 
28.03*** 
 
.90 
 
.66 
 
.90 
 
Emotional  
 
FA06 
FA07 
FA082 
 
.82 
.83 
.79 
 
26.89 *** 
25.44*** 
 
.85 
 
.66 
 
.85 
 
Cognitive  
 
FA09 
FA102 
 
.87 
.78 
  
20.96 *** 
 
.82 
 
.70 
 
.81 
1 following [16]; 2 = no t-values, fixed reference parameters to standardize the variance of the construct  
 *** = p <.001 
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Table 5 Sensitivity to change in Group A (curative treatment) (MANOVA, data of t1A to t3A) 
 
  t1   t2   t3         
 Dimension M SD M SD M SD Pillai 
-Bartlett's V 
(df) 
 
ηp²  
(partial 
eta-
squared) 
Pair wise 
comparison 
Physical Fatigue 
n=225 
1.99 0.79 2.33 0.79 2.05 0.76 26.59* 
(2,230) 
0.19 
 
t1 & t2* 
t2 & t3* 
Emotional Fatigue 
n =230 
1.78 0.76 1.89 0.70 1.68 0.74 13.87* 
(2,230) 
0.11 t1 & t2* 
t2 & t3* 
Cognitive  
Fatigue 
n = 228 
1.45 0.56 1.58 0.59 1.43 0.56 11.38* 
(2,230) 
0.09 t1 & t2* 
t2 & t3* 
          
Multivariate effect of 
time  
n = 228 
      21.28*** 
(2,229) 
0.16  
Multivariate interaction effect 
of 
time and dimension 
n =228 
      9.72*** 
(4,227) 
0.15  
* = p <.05, *** = p <.001 
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Table 6 Sensitivity to change in Group B (palliative treatment) (MANOVA, data of t1B to t3B) 
 
  t1   t2   t3         
 Dimension M SD M SD M SD Pillai 
-Bartlett's V 
(df) 
 
ηp² 
(eta-
squared) 
Pair wise 
comparison 
Physical. 
Fatigue 
n = 135 
2.30 0.79 2.36 0.77 2.44 0.79 1.73 
(2,230) 
0.03 
 
n.s.  
Emotional 
Fatigue 
n = 132 
2.09 0.79 2.03 0.74 2.15 0.84 1.99 
(2,230) 
0.03 
 
n.s.  
Cognitive 
Fatigue 
n = 134 
1.65 0.58 1.63 0.49 1.77 0.65 3.99* 
(2,230) 
0.06 
 
t2 & t3* 
          
Multivariate effect of 
time 
n=132 
      2.89 
(2,229) 
0.04  
Multivariate interaction 
effect of 
time and dimension 
n =132 
      1.4 
(4,227) 
0.04  
* = p <.05 
 
 
  
 23 
 
 
Table 7 Internal reliability and intraclass correlation (data of t1CD, t2CD) 
 Dimension Cronbachs α t1 (group C & D) Cronbachs α t2 (group C & D) Intraclass Corr  
(group C and D)  
mean score Rt1-t2 
Physical  
Fatigue 
(n = 410)               .88 (n = 386)              .90 .921*** 
Emotional 
Fatigue 
(n = 402)               .87 (n = 388)              .88 .905*** 
Cognitive  
Fatigue 
(n = 408)               .79 (n = 389)              .82 .907*** 
 *** = p <.001 
 
 
